paclitaxel + doxorubicin + cyclophosphamide

This refers to a metronomic chemotherapy regimen developed by the **Instituto do Cancer do Estado de São Paulo (ICESP)** for the neoadjuvant treatment of locally advanced HER2-negative breast cancer. The regimen, investigated in the **TAME-01** phase II feasibility study, consists of a sequential administration of weekly paclitaxel followed by weekly doxorubicin combined with daily oral cyclophosphamide. Unlike traditional high-dose chemotherapy, this metronomic approach utilizes lower, more frequent dosing without granulocyte colony-stimulating factor (G-CSF) support, aiming to maintain efficacy while minimizing hematological and systemic toxicity by potentially inhibiting tumor angiogenesis and altering the tumor microenvironment.

Other names

Metronomic Paclitaxel, Doxorubicin, and CyclophosphamideTAME regimen